| An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors (NCT05481502) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-06-08 |
| Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT (NCT05493800) | MitoImmune Therapeutics | 2022-02-01 |
| Avera Cancer Sequencing and Analytics Protocol (ASAP) (NCT05142033) | Avera McKennan Hospital & University Health Center | 2021-11-01 |
| Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT (NCT04966156) | University Health Network, Toronto | 2021-09-08 |
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS (NCT05175508) | The First Affiliated Hospital of Soochow University | 2021-05-01 |
| TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS (NCT04822974) | Institut Paoli-Calmettes | 2021-05-01 |
| Coverage and Cost-of-Care (CC) Links- Financial Navigation Program (NCT05465577) | Jean Edward | 2021-04-01 |
| The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality (NCT04412135) | University Hospital, Limoges | 2020-06-01 |
| QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management (NCT05626764) | Hospices Civils de Lyon | 2020-01-27 |
| Symptom Management for YA Cancer Survivors (NCT04035447) | Duke University | 2020-01-22 |
| CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients (NCT04235153) | Hospices Civils de Lyon | 2020-01-09 |
| Research-Action in Hematology From Hospitalization to Home (NCT06053918) | University Hospital, Caen | 2019-05-07 |
| An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme) (NCT03955276) | University of California, San Diego | 2019-02-07 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) (NCT03091933) | Ciusss de L'Est de l'Île de Montréal | 2017-02-06 |
| Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples (NCT01792882) | Global BioClinical | 2013-02-01 |
| A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma (NCT00742560) | AbbVie (prior sponsor, Abbott) | 2008-08-01 |